Share-based Payment Arrangement, Expense of Theravance Biopharma, Inc. from 31 Dec 2012 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Theravance Biopharma, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2012 to 30 Sep 2025.
  • Theravance Biopharma, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $4,576,000, a 7.8% decline year-over-year.
  • Theravance Biopharma, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $19,821,000, a 7.3% decline year-over-year.
  • Theravance Biopharma, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $21,393,000, a 16% decline from 2023.
  • Theravance Biopharma, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $25,371,000, a 36% decline from 2022.
  • Theravance Biopharma, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $39,734,000, a 36% decline from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Theravance Biopharma, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $19,821,000 $4,576,000 -$387,000 -7.8% 01 Jul 2025 30 Sep 2025 10-Q 12 Nov 2025 2025 Q3
Q2 2025 $20,208,000 $4,543,000 -$833,000 -15% 01 Apr 2025 30 Jun 2025 10-Q 13 Aug 2025 2025 Q2
Q1 2025 $21,041,000 $4,877,000 -$352,000 -6.7% 01 Jan 2025 31 Mar 2025 10-Q 12 May 2025 2025 Q1
Q4 2024 $21,393,000 $5,825,000 +$1,000 +0.02% 01 Oct 2024 31 Dec 2024 10-K 07 Mar 2025 2024 FY
Q3 2024 $21,392,000 $4,963,000 -$1,299,000 -21% 01 Jul 2024 30 Sep 2024 10-Q 12 Nov 2025 2025 Q3
Q2 2024 $22,691,000 $5,376,000 -$888,000 -14% 01 Apr 2024 30 Jun 2024 10-Q 13 Aug 2025 2025 Q2
Q1 2024 $23,579,000 $5,229,000 -$1,792,000 -26% 01 Jan 2024 31 Mar 2024 10-Q 12 May 2025 2025 Q1
Q4 2023 $25,371,000 $5,824,000 -$1,126,000 -16% 01 Oct 2023 31 Dec 2023 10-K 07 Mar 2025 2024 FY
Q3 2023 $26,497,000 $6,262,000 -$2,268,000 -27% 01 Jul 2023 30 Sep 2023 10-Q 14 Nov 2024 2024 Q3
Q2 2023 $28,765,000 $6,264,000 -$3,445,000 -35% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 $32,210,000 $7,021,000 -$7,524,000 -52% 01 Jan 2023 31 Mar 2023 10-Q 15 May 2024 2024 Q1
Q4 2022 $39,734,000 $6,950,000 -$9,968,000 -59% 01 Oct 2022 31 Dec 2022 10-K 01 Mar 2024 2023 FY
Q3 2022 $49,702,000 $8,530,000 -$5,840,000 -41% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023 2023 Q3
Q2 2022 $55,542,000 $9,709,000 -$5,232,000 -35% 01 Apr 2022 30 Jun 2022 10-Q 09 Aug 2023 2023 Q2
Q1 2022 $60,774,000 $14,545,000 -$1,287,000 -8.1% 01 Jan 2022 31 Mar 2022 10-Q 10 May 2023 2023 Q1
Q4 2021 $62,061,000 $16,918,000 +$1,367,000 +8.8% 01 Oct 2021 31 Dec 2021 10-K 01 Mar 2023 2022 FY
Q3 2021 $60,694,000 $14,370,000 -$1,194,000 -7.7% 01 Jul 2021 30 Sep 2021 10-Q 09 Nov 2022 2022 Q3
Q2 2021 $61,888,000 $14,941,000 -$1,644,000 -9.9% 01 Apr 2021 30 Jun 2021 10-Q 08 Aug 2022 2022 Q2
Q1 2021 $63,532,000 $15,832,000 +$556,000 +3.6% 01 Jan 2021 31 Mar 2021 10-Q 06 May 2022 2022 Q1
Q4 2020 $62,976,000 $15,551,000 -$8,362,000 -35% 01 Oct 2020 31 Dec 2020 10-K 01 Mar 2023 2022 FY
Q3 2020 $71,338,000 $15,564,000 +$2,545,000 +20% 01 Jul 2020 30 Sep 2020 10-Q 08 Nov 2021 2021 Q3
Q2 2020 $68,793,000 $16,585,000 +$5,287,000 +47% 01 Apr 2020 30 Jun 2020 10-Q 05 Aug 2021 2021 Q2
Q1 2020 $63,506,000 $15,276,000 +$3,056,000 +25% 01 Jan 2020 31 Mar 2020 10-Q 06 May 2021 2021 Q1
Q4 2019 $60,450,000 $23,913,000 +$12,199,000 +104% 01 Oct 2019 31 Dec 2019 10-K 28 Feb 2022 2021 FY
Q3 2019 $48,251,000 $13,019,000 +$1,273,000 +11% 01 Jul 2019 30 Sep 2019 10-Q 09 Nov 2020 2020 Q3
Q2 2019 $46,978,000 $11,298,000 -$2,557,000 -18% 01 Apr 2019 30 Jun 2019 10-Q 10 Aug 2020 2020 Q2
Q1 2019 $49,535,000 $12,220,000 -$1,778,000 -13% 01 Jan 2019 31 Mar 2019 10-Q 08 May 2020 2020 Q1
Q4 2018 $51,313,000 $11,714,000 -$6,079,000 -34% 01 Oct 2018 31 Dec 2018 10-K 26 Feb 2021 2020 FY
Q3 2018 $57,392,000 $11,746,000 +$1,061,000 +9.9% 01 Jul 2018 30 Sep 2018 10-Q 08 Nov 2019 2019 Q3
Q2 2018 $56,331,000 $13,855,000 +$3,457,000 +33% 01 Apr 2018 30 Jun 2018 10-Q 05 Aug 2019 2019 Q2
Q1 2018 $52,874,000 $13,998,000 +$3,729,000 +36% 01 Jan 2018 31 Mar 2018 10-Q 10 May 2019 2019 Q1
Q4 2017 $49,145,000 $17,793,000 +$7,753,000 +77% 01 Oct 2017 31 Dec 2017 10-K 27 Feb 2020 2019 FY
Q3 2017 $41,392,000 $10,685,000 +$790,000 +8% 01 Jul 2017 30 Sep 2017 10-Q 08 Nov 2018 2018 Q3
Q2 2017 $40,602,000 $10,398,000 +$494,000 +5% 01 Apr 2017 30 Jun 2017 10-Q 02 Aug 2018 2018 Q2
Q1 2017 $40,108,000 $10,269,000 -$1,061,000 -9.4% 01 Jan 2017 31 Mar 2017 10-Q 09 May 2018 2018 Q1
Q4 2016 $41,169,000 $10,040,000 -$1,471,000 -13% 01 Oct 2016 31 Dec 2016 10-K 28 Feb 2019 2018 FY
Q3 2016 $42,640,000 $9,895,000 -$2,356,000 -19% 01 Jul 2016 30 Sep 2016 10-Q 08 Nov 2017 2017 Q3
Q2 2016 $44,996,000 $9,904,000 -$4,758,000 -32% 01 Apr 2016 30 Jun 2016 10-Q 09 Aug 2017 2017 Q2
Q1 2016 $49,754,000 $11,330,000 -$4,296,000 -27% 01 Jan 2016 31 Mar 2016 10-Q 10 May 2017 2017 Q1
Q4 2015 $54,050,000 $11,511,000 -$2,908,000 -20% 01 Oct 2015 31 Dec 2015 10-K 28 Feb 2018 2017 FY
Q3 2015 $56,958,000 $12,251,000 +$2,901,000 +31% 01 Jul 2015 30 Sep 2015 10-Q 09 Nov 2016 2016 Q3
Q2 2015 $54,057,000 $14,662,000 +$7,898,000 +117% 01 Apr 2015 30 Jun 2015 10-Q 09 Aug 2016 2016 Q2
Q1 2015 $46,159,000 $15,626,000 +$2,925,000 +23% 01 Jan 2015 31 Mar 2015 10-Q 10 May 2016 2016 Q1
Q4 2014 $43,234,000 $14,419,000 +$9,260,000 +179% 01 Oct 2014 31 Dec 2014 10-K 01 Mar 2017 2016 FY
Q3 2014 $33,974,000 $9,350,000 +$3,756,000 +67% 01 Jul 2014 30 Sep 2014 10-Q 12 Nov 2015 2015 Q3
Q2 2014 $30,218,000 $6,764,000 +$557,000 +9% 01 Apr 2014 30 Jun 2014 10-Q 13 Aug 2015 2015 Q2
Q1 2014 $29,661,000 $12,701,000 +$7,185,000 +130% 01 Jan 2014 31 Mar 2014 10-Q 13 May 2015 2015 Q1
Q4 2013 $22,476,000 $5,159,000 01 Oct 2013 31 Dec 2013 10-K 11 Mar 2016 2015 FY
Q3 2013 $5,594,000 01 Jul 2013 30 Sep 2013 10-Q 12 Nov 2014 2014 Q3
Q2 2013 $6,207,000 01 Apr 2013 30 Jun 2013 10-Q 14 Aug 2014 2014 Q2
Q1 2013 $5,516,000 01 Jan 2013 31 Mar 2013 10-Q 24 Jun 2014 2014 Q1

Theravance Biopharma, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $21,393,000 -$3,978,000 -16% 01 Jan 2024 31 Dec 2024 10-K 07 Mar 2025 2024 FY
2023 $25,371,000 -$14,363,000 -36% 01 Jan 2023 31 Dec 2023 10-K 07 Mar 2025 2024 FY
2022 $39,734,000 -$22,327,000 -36% 01 Jan 2022 31 Dec 2022 10-K 01 Mar 2024 2023 FY
2021 $62,061,000 -$915,000 -1.5% 01 Jan 2021 31 Dec 2021 10-K 01 Mar 2023 2022 FY
2020 $62,976,000 +$2,526,000 +4.2% 01 Jan 2020 31 Dec 2020 10-K 01 Mar 2023 2022 FY
2019 $60,450,000 +$9,137,000 +18% 01 Jan 2019 31 Dec 2019 10-K 28 Feb 2022 2021 FY
2018 $51,313,000 +$2,168,000 +4.4% 01 Jan 2018 31 Dec 2018 10-K 26 Feb 2021 2020 FY
2017 $49,145,000 +$7,976,000 +19% 01 Jan 2017 31 Dec 2017 10-K 27 Feb 2020 2019 FY
2016 $41,169,000 -$12,881,000 -24% 01 Jan 2016 31 Dec 2016 10-K 28 Feb 2019 2018 FY
2015 $54,050,000 +$10,816,000 +25% 01 Jan 2015 31 Dec 2015 10-K 28 Feb 2018 2017 FY
2014 $43,234,000 +$20,758,000 +92% 01 Jan 2014 31 Dec 2014 10-K 01 Mar 2017 2016 FY
2013 $22,476,000 +$1,153,000 +5.4% 01 Jan 2013 31 Dec 2013 10-K 11 Mar 2016 2015 FY
2012 $21,323,000 01 Jan 2012 31 Dec 2012 10-K 13 Mar 2015 2014 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.